in first-line lung cancer patients
Sac-TMT (sacituzumab tirumotecan) is co-owned and co-developed by Kelun-Biotech (a subsidiary of Sichuan Kelun Pharmaceutical- China) and Merck & Co. (known as MSD outside the U.S. and Canada)
https://endpoints.news/merck-plans-trial-of-s...or=expired
and on linked in -
"Merck CEO Rob Davis has transformed the firm into pharma’s top dealmaker, spending $26bn on acquisitions in the past year to diversify beyond oncology into infectious and respiratory diseases. This aggressive M&A strategy is driven by an urgent impending patent cliff, Keytruda, Merck’s blockbuster cancer drug and the world's best-selling medicine. Keytruda generated $31.7bn last year (nearly 50% of Merck’s total revenue) but loses patent protection in 2028. To survive this massive boom-and-bust cycle, Davis is hunting for biotech bolt-on deals. Despite the looming cliff, Davis insists the market underappreciates Merck’s internal progress, boasting the richest Phase 1, 2, and 3 clinical pipeline in the company’s history..."
https://www.linkedin.com/posts/wajahat-afaq-5...2930-L9ed/
now what could possibly be a wise acquisition that could address cancer AND respiratory diseases? hmmmmm